Amnon Peled, Izhar Hardan, Luba Trakhtenbrot, Eyal Gur, Michal Magid, Merav Darash-Yahana, Ninette Cohen, Valentin Grabovsky, Suzana Franitza, Orit Kollet, Ofer Lider, Ronen Alon, Gideon Rechavi, Tsvee Lapidot
Chronic myelogenous leukemia (CML), a malignant myeloproliferative disorder originating from a pluripotent stem cell expressing the bcr-abl oncogene, is characterized by abnormal release of the expanded, malignant stem cell clone from the bone marrow (BM) into the circulation. Moreover, immature CD34+ CML cells have lower adhesion to stromal cells and fibronectin as well as lower engraftment potential in severe combined immunedeficient (SCID) and nonobese diabetic (NOD)/SCID mice than normal CD34+ cells. We report in this study that leukemic Philadelphia chromosome-positive (Ph+)CD34+ cells from newly diagnosed CML patients that express the chemokine receptor CXCR4 migrate in response to stromal-derived factor-1 (SDF-1)...
2002: Stem Cells